S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48

Lipocine Stock Forecast, Price & News

-0.01 (-1.03%)
(As of 01/19/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
282,848 shs
Average Volume
547,046 shs
Market Capitalization
$84.71 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive LPCN News and Ratings via Email

Sign-up to receive the latest news and ratings for Lipocine and its competitors with MarketBeat's FREE daily newsletter.

Lipocine logo

About Lipocine

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development for the delivery of drugs using proprietary delivery technology. The firm involves in applying oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. It offers TLANDO, an oral testosterone replacement therapy. The company was founded in 2011 and is headquartered in Salt Lake City, UT.


LPCN.OQ - Lipocine Inc Profile - Reuters
November 21, 2021 |  reuters.com
LPCN: Third Quarter Update
November 11, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$170 thousand
Book Value
$0.19 per share


Net Income
$-20.96 million
Pretax Margin




Free Float
Market Cap
$84.71 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.12 out of 5 stars

Medical Sector

498th out of 1,415 stocks

Pharmaceutical Preparations Industry

231st out of 682 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Lipocine (NASDAQ:LPCN) Frequently Asked Questions

Is Lipocine a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lipocine in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Lipocine stock.
View analyst ratings for Lipocine
or view top-rated stocks.

How has Lipocine's stock been impacted by COVID-19?

Lipocine's stock was trading at $0.4511 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, LPCN shares have increased by 112.7% and is now trading at $0.9594.
View which stocks have been most impacted by COVID-19

When is Lipocine's next earnings date?

Lipocine is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Lipocine

How were Lipocine's earnings last quarter?

Lipocine Inc. (NASDAQ:LPCN) issued its quarterly earnings results on Wednesday, November, 10th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter, topping the Zacks' consensus estimate of ($0.04) by $0.01. The specialty pharmaceutical company earned $0.06 million during the quarter.
View Lipocine's earnings history

What price target have analysts set for LPCN?

2 equities research analysts have issued twelve-month target prices for Lipocine's stock. Their forecasts range from $3.00 to $3.50. On average, they anticipate Lipocine's share price to reach $3.25 in the next year. This suggests a possible upside of 238.8% from the stock's current price.
View analysts' price targets for Lipocine
or view top-rated stocks among Wall Street analysts.

Who are Lipocine's key executives?

Lipocine's management team includes the following people:
  • Mahesh V. Patel, Chairman, President & Chief Executive Officer
  • Morgan R. Brown, Chief Financial Officer & Executive Vice President
  • Anthony DelConte, Chief Medical Director
  • Nachiappan Chidambaram, Vice President-Product Development
  • Hans Vitzthum, Head-Investors Relation Contact

What other stocks do shareholders of Lipocine own?

What is Lipocine's stock symbol?

Lipocine trades on the NASDAQ under the ticker symbol "LPCN."

How do I buy shares of Lipocine?

Shares of LPCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lipocine's stock price today?

One share of LPCN stock can currently be purchased for approximately $0.96.

How much money does Lipocine make?

Lipocine has a market capitalization of $84.71 million and generates $170 thousand in revenue each year. The specialty pharmaceutical company earns $-20.96 million in net income (profit) each year or ($0.21) on an earnings per share basis.

How many employees does Lipocine have?

Lipocine employs 11 workers across the globe.

What is Lipocine's official website?

The official website for Lipocine is www.lipocine.com.

Where are Lipocine's headquarters?

How can I contact Lipocine?

Lipocine's mailing address is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. The specialty pharmaceutical company can be reached via phone at (801) 994-7383, via email at [email protected], or via fax at 801-994-7388.

This page was last updated on 1/20/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.